VASCERN’s COVID19 recommendations

VASCERN COVID-19 Recommendations

With the current global spread of the novel coronavirus SARS Cov-2, causing COVID-19, the experts from the Rare Disease Working Groups of VASCERN have prepared the following consensus statements for patients with rare vascular diseases. These statements will be updated as necessary.

General COVID-19 Statements

Hereditary Haemorrhgic Telangiectasia (HHT)

VASCERN Hereditary Haemorrhagic Telangiectasia (HHT) Statement on COVID-19

Heritable Thoracic Aortic Diseases (HTAD)

VASCERN Heritable Thoracic Aortic Diseases (HTAD) Working Group statement on COVID-19

This statement can equally be found in:

Dutch: VASCERN HTAD verklaring over Covid 19

French: Déclaration du groupe de travail VASCERN sur les maladies aortiques thoraciques héréditaires (HTAD) sur COVID-19

German: VASCERN Erklärung zu Covid 19

Maltese: Stqarrija mill-VASCERN HTAD WG dwar il-COVID-19

Spanish: Declaración de VASCERN HTAD sobre Covid 19

Pediatric and Primary Lymphedema (PPL)

The Pediatric and Primary Lymphedema (PPL) Working Group endorses the COVID-19 statement by the Lymphoedema Support Network

German translation available here

Medium sized Arteries (MSA)

VASCERN Medium-Sized Arteries (MSA) Working Group statement on COVID-19 (March 2020)

Vascular Anomalies (VASCA)

VASCERN Vascular Anomalies (VASCA) Working Group COVID-19 Statement– initiated by the patient advocacy groups in Europe and the United States and their medical advisory teams and approved by the VASCA WG.

This statement can equally be found in:

French: Information COVID-19 pour les patients porteurs d’ Anomalies Vasculaires et/ou Lymphatiques

Finnish: VASCERN Suonipoikkeavuuksien (VASCA) työryhmä – Tietoa koronaviruksesta (COVID-19) potilaille, joilla on vaikea suonipoikkeavuus